Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

被引:0
作者
Adil Daud
Japinder Gill
Sheily Kamra
Lei Chen
Amit Ahuja
机构
[1] University of California,Medicine and Dermatology
[2] PAREXEL International,undefined
[3] Novartis Pharmaceuticals Corporation,undefined
来源
Journal of Hematology & Oncology | / 10卷
关键词
Dabrafenib; Trametinib; Vemurafenib; Cobimetinib; Metastatic melanoma; Indirect treatment comparison;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 123 条
[1]  
Algazi AP(2010)Treatment of cutaneous melanoma: current approaches and future prospects Cancer Manag Res. 2 197-211
[2]  
Soon CW(2012)Therapy for metastatic melanoma: the past, present, and future BMC Med. 10 23-85
[3]  
Daud AI(2004)Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma Br J Dermatol 150 179-400
[4]  
Finn L(2013)International trends in the incidence of malignant melanoma 1953–2008—are recent generations at higher or lower risk? Int J Cancer. 132 385-47
[5]  
Markovic SN(2005)Distinct sets of genetic alterations in melanoma N Engl J Med. 353 2135-54
[6]  
Joseph RW(2002)Mutations of the BRAF gene in human cancer Nature. 417 949-20
[7]  
Lens MB(2010)The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-κB/Snail/RKIP/PTEN circuit Genes Cancer. 1 409-87
[8]  
Dawes M(2011)The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep 13 479-46
[9]  
Erdmann F(2011)Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol. 29 1239-16
[10]  
Lortet-Tieulent J(2011)Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med. 364 2507-65